GCTK Stock Risk & Deep Value Analysis
GlucoTrack Inc
DVR Score
out of 10
What You Need to Know About GCTK Stock
We analyzed GlucoTrack Inc using our deep value framework. Sign in to see our full verdict and DVR Score.
We ran GCTK through our deep value framework — analyzing financial health, distress signals, competitive moat, and risk factors. Our risk assessment: Aggressive. Here's what we found.
GCTK Risk Analysis & Red Flags
What Could Go Wrong
The company faces imminent financial collapse as indicated by the "going concern" warning. With only $7.4 million in cash and recurring losses, they will likely run out of capital quickly, leading to further highly dilutive capital raises, potential bankruptcy, or delisting before any meaningful clinical or regulatory milestones can be achieved.
Risk Matrix
Overall
Aggressive
Financial
High
Market
Medium
Competitive
High
Execution
High
Regulatory
High
Red Flags
- ⚠
Auditor's "going concern" warning in FY 2025 10-K
- ⚠
$151.8 million accumulated deficit and recurring operating losses
- ⚠
Only $7.4 million cash and cash equivalents as of December 31, 2025 (limited runway)
- ⚠
Significant share dilution from December 2025 capital raise
- ⚠
Negligible market capitalization ($0.00B as provided) indicating extreme distress or low liquidity
- ⚠
Lack of quantitative revenue or profitability data in recent earnings announcements
Upcoming Risk Events
- 📅
Q3 2026: Failure to secure additional funding, leading to insolvency
- 📅
Q4 2026: Rejection or significant delay of FDA IDE application
When to Reconsider
- 🚪
Failure to secure additional funding by Q3 2026
- 🚪
Rejection or significant delay of FDA IDE application for clinical trial
- 🚪
Announcements of further highly dilutive capital raises that significantly reduce per-share value
Unlock GCTK Risk Analysis & Red Flags
Create a free account to see the full analysis
Investment Thesis
GlucoTrack is an extremely high-risk, speculative 'lottery ticket' investment. Its bull case rests solely on the successful, multi-year, capital-intensive journey of gaining FDA approval for its implantable Continuous Blood Glucose Monitoring (CBGM) system, which could potentially disrupt a massive market. However, immediate financial solvency issues, recurring losses, and the significant regulatory hurdles make it highly probable that the company will fail before achieving commercialization.
Is GCTK Stock Undervalued?
Unlock the full AI analysis for GCTK
Get the complete DVR score, risk analysis, and more
Unlock the full report
Create a free account to see the DVR score, risk flags, and AI analysis.
GCTK Price Targets & Strategy
12-Month Target
$0.10
Bull Case
$1.50
Bear Case
$0.01
Valuation Basis
Based on speculative market cap near cash value for upside, and high probability of further dilution/insolvency for downside, given the 'going concern' warning and pre-revenue stage.
Entry Strategy
Extreme caution advised; any entry is purely speculative. Consider a nominal position only if FDA IDE approval is announced, using a stop-loss order.
Exit Strategy
Take profit on any significant positive regulatory news (e.g., IDE approval). Implement a hard stop-loss if price drops below $0.10 or if additional dilutive financing is announced without substantial progress.
Portfolio Allocation
0.05% for aggressive, highly speculative risk tolerance (treat as a lottery ticket).
Price Targets & Strategy
Upgrade to Premium for price targets and entry/exit strategies
Is GCTK Financially Healthy?
Valuation
P/E Ratio
-31.22
Balance Sheet
Cash & Equivalents
$7.40M
Does GCTK Have a Competitive Moat?
Sign in to unlockMoat Rating
⚪ None
Moat Trend
Nascent/Eroding (The intellectual property is developing, but severe financial distress threatens any ability to commercialize and defend it, leading to erosion risk)
Moat Sources
1 Identified
Highly uncertain; current patents offer theoretical protection, but without successful clinical trials, FDA approval, and commercialization, they provide no durable competitive advantage. The severe financial risk makes long-term moat formation unlikely.
Moat Erosion Risks
- •Failure to secure FDA approval for its device
- •Inability to fund further R&D and clinical trials
- •Competition from established CGM players developing similar or superior technologies
- •Erosion of IP through challenges or alternative technologies
GCTK Competitive Moat Analysis
Sign up to see competitive advantages
GCTK Market Intelligence
Sentiment & Insider Activity
Social Sentiment
Bearish (Likely due to persistent financial concerns and stock price decline)
Institutional Sentiment
Negative (No analyst coverage, no reported institutional ownership, and significant price decline suggests disinterest)
Insider Activity (Form 4)
No Form 4 filings or insider transactions reported in the last 90 days (Neutral, but absence of buying at depressed levels is a concern).
Options Flow
Normal options activity (No specific unusual options activity reported).
Earnings Intelligence
Next Earnings
Estimated mid-May 2026 (for Q1 2026 results)
Surprise Probability
Low (No consensus estimates available, history of losses)
Historical Earnings Pattern
Likely volatile on any news regarding financing or regulatory progress; otherwise, generally a downward trend given current fundamentals.
Key Metrics to Watch
Competitive Position
Top Competitor
DEXCOM
Market Share Trend
0% (Pre-commercialization stage)
Valuation vs Peers
Not comparable due to pre-revenue status, 'going concern' warning, and unique implantable device approach. Established CGM peers (Dexcom, Abbott) are profitable and have approved products.
Competitive Advantages
- •Proprietary patented technology for implantable CBGM (if successful)
- •Potential for highly differentiated product in the future
Market Intelligence
Get sentiment, earnings intel, and peer analysis with Premium
What Could Drive GCTK Stock Higher?
Near-Term (0-6 months)
- •Q2 2026: Filing of FDA IDE for implantable CBGM
- •Mid-2026: Announcement of new financing round (potentially dilutive)
Medium-Term (6-18 months)
- •H2 2026: Start of U.S. clinical trial (pending IDE approval)
- •Early 2027: Initial interim clinical trial data
Long-Term (18+ months)
- •2028-2029+: Potential full FDA approval of implantable CBGM
- •Post-2029: Commercialization and market penetration
Catalysts & Growth Drivers
Upgrade to Premium to see catalysts
What's the Bull Case for GCTK?
- ✓
Successful FDA IDE approval and start of U.S. clinical trials
- ✓
Announcement of significant non-dilutive or strategic financing
- ✓
Quantitative updates on cash runway and burn rate
Bull Case Analysis
See what could go right with Premium
📊 Explore More Stock Analysis
Get comprehensive Deep Value Reports for thousands of stocks. Research risk, financial health, and investment potential with our AI-powered analysis.
How GlucoTrack Inc Makes Money
GlucoTrack Inc. is an early-stage medical device company that does not currently generate significant revenue. Its business model is centered on developing an implantable Continuous Blood Glucose Monitor (CBGM) for individuals with diabetes, aiming to provide a more convenient and accurate method of glucose tracking. The company relies heavily on external capital raises to fund its extensive research, development, and stringent regulatory approval processes (primarily with the FDA). If successful, its future revenue would stem from the sale of its implantable devices and associated monitoring systems to patients and healthcare providers, potentially through licensing or direct sales channels, transforming it into a medical device manufacturer and service provider.
Read Full Business Model BreakdownFAQ
What is the DVR Score for GlucoTrack Inc (GCTK)?
As of April 12, 2026, GlucoTrack Inc has a DVR Score of 1.0 out of 10, placing it in the "Distressed" category. This score is generated by our AI-powered deep value analysis framework that evaluates growth potential, financial health, competitive moat, and risk factors.
What is the risk level for GCTK stock?
Our analysis rates GlucoTrack Inc's overall risk as Aggressive. This assessment considers execution risk, market risk, financial risk, competitive risk, and regulatory risk. For a full breakdown, see the risk analysis section above.
What is the P/E ratio of GCTK?
GlucoTrack Inc currently has a price-to-earnings (P/E) ratio of -31.2. This is below the market average, which could indicate the stock is undervalued or facing headwinds.
Is GlucoTrack Inc's revenue growing?
GlucoTrack Inc has reported revenue growth of 0.0%. Revenue has been declining, which warrants closer examination.
Is GCTK stock profitable?
GlucoTrack Inc has a profit margin of 0.0%. The company is currently unprofitable.
How often is the GCTK DVR analysis updated?
Our AI-powered analysis of GlucoTrack Inc is refreshed regularly to incorporate the latest financial data, market conditions, and news. The most recent update was on April 12, 2026.
Important Disclaimer – Not Financial Advice
Deep Value Reports is an independent research platform for educational and informational purposes only. We are not financial advisors, investment advisors, or licensed professionals. The analysis, scores, and information provided on this page for GCTK (GlucoTrack Inc) should not be construed as personalized investment advice, a recommendation to buy or sell any security, or an offer to provide investment advisory services.
All investments involve risk, including the potential loss of principal. Past performance does not guarantee future results. Always conduct your own research, consider your financial situation, and consult with a qualified financial advisor before making any investment decisions.